Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

SV Health Investors (Group)

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.2B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs. Historically, SV managed funds have been diversified across the three sectors. However, the firm’s seventh vintage of core funds is separated into three distinct vehicles; the SV7 Impact Medicine Fund forms and funds early-stage biotechnology companies developing precision medicines, the Growth Fund accelerates growth-stage healthcare services, medical products and digital health companies and the Medtech Convergence Fund specialises in novel medical device and remote-monitoring technologies. Alongside their core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia, and the International Biotechnology Trust plc, a publicly-traded investment trust. *


Period Start 2017-04-10 renamed
  Predecessor SV Life Sciences (SVLS) (Group)
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Ross, Mike (SV Health Investors 202009 Managing Partner)
  Person 2 Burgess, Daniel (Dan) (Pulmocide 202105 CEO + Venture Partner at SV Health Investors before Rempex + Mpex)
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 71 Kingsway
  City WC2B 6ST London
  Tel +44-20-7421-7070
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2015-12-02)
  Currency USD
  Annual sales 2,200,000,000 (assets, managed (2020) 2020-09-15)
    * Document for �About Section�: Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London.
Record changed: 2021-05-29


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for SV Health Investors (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top